GSK to close Stiefel Laboratories manufacturing faclility in Ireland

| By | Drug Manufacturing, GSK
0
235

GlaxoSmithKline (GSK) plans to close its dermatology subsidiary plant in Sligo (Ireland). The plant is to wind down, with final closure tabled for 2021.

Stiefel Laboratories, a global dermatological pharmaceutical company, was founded in Germany, in 1847, and is currently owned by GSK. Stiefel’s headquarters located in Research Triangle Park, North Carolina (USA).

GSK informed employees at the skincare manufacturing site about the plans to phase down production over the next three years. According to GSK the demand for its skincare products had not materialised. Other GSK factories in Ireland will not be affected by the decision. GSK employs 1500 people across four locations in Ireland. The Stiefel plant was threatened with closure before in 2009 after GSK acquired the company, but the decision was reversed. GSK has been in Sligo for the past 43 years and the plant is a dedicated supply site for Stiefel skincare products.

SOURCE: silicon republic
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.